2012 Brazilian Society of Rheumatology Consensus on the management of comorbidities in patients with rheumatoid arthritis

Revista Brasileira de Reumatologia

Volumn 52, Issue 4, 2012, Pages 483-495

  Pereira, Ivânio Alves ^a,b   Mota, Licia Maria Henrique da ^c   Cruz, Boris Afonso ^d   Brenol, Claiton Viegas ^e   Fronza, Lucila Stange Rezende ^f   Bertolo, Manoel Barros ^g   Freitas, Max Victor Carioca de ^h   Silva, Nilzio Antônio da ⁱ   Louzada Junior, Paulo ^j   Giorgi, Rina Dalva Neubarth ^k   Lima, Rodrigo Aires Corrêa ^l   Pinheiro, Geraldo da Rocha Castelar ^m  

^a UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c UNIVERSITY OF BRASILIA   (Brazil)

^d BIOCOR INSTITUTO   (Brazil)

^e FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^f FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^g UNIVERSITY OF CAMPINAS   (Brazil)

^h FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

ⁱ FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^j UNIVERSITY OF SÃO PAULO   (Brazil)

^k HOSPITAL DO SERVIDOR PÚBLICO ESTADUAL DE SÃO PAULO   (Brazil)

^l HOSPITAL UNIVERSITÁRIO DE BRASÍLIA   (Brazil)

^m STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

more..

Author keywords

Arterial hypertension; Comorbidities; Diabetes mellitus; dyslipidemia; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DIURETIC AGENT; ETANERCEPT; GLUCOCORTICOID; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RITUXIMAB; TUMOR NECROSIS FACTOR DERIVATIVE; VITAMIN D;

ARTICLE; ATHEROSCLEROSIS; BONE DENSITOMETRY; BRAZIL; CALCIUM INTAKE; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONSENSUS; DIABETES MELLITUS; DIETARY INTAKE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; EXERCISE; HEALTH CARE MANAGEMENT; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INCIDENCE; LUNG EMBOLISM; MALIGNANT NEOPLASTIC DISEASE; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; RISK ASSESSMENT; SUN EXPOSURE; SYSTEMATIC REVIEW; VEIN THROMBOSIS;

ARTHRITIS, RHEUMATOID; HUMANS;

EID: 84866563479     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0482-50042012000400002     Document Type: Article

References (116)

1. McInnes IB, O'Dell JR. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 2010; 69(11):1898-906. [Erratum in: Ann Rheum Dis 2011; 70(2):399]
2. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365(23):2205-19.
3. Allaart CF, Huizinga TW. Treatment strategies in recent onset rheumatoid arthritis. Curr Opin Rheumatol 2011; 23(3):241-4.
4. Symmons DP. Rheumatoid arthritis: assessing disease activity and outcome. Clin Med 2010; 10(3):248-51.
5. Gonzalez A, Maradit Kremers H, Crowson CS, Nicola PJ, Davis JM 3rd, Therneau TM et al.. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007; 56(11):3583-7.
6. Hemminki K, Li X, Sundquist J, Sundquist K. Familial associations of rheumatoid arthritis with autoimmune diseases and related conditions. Arthritis Rheum 2009; 60(3):661-8.
7. Michou L, Rat AC, Lasbleiz S, Bardin T, Cornélis F. Prevalence and distribution of autoimmune diseases in 368 rheumatoid arthritis families. J Rheumatol 2008; 35(5):790-6.
8. Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007; 21(5):885-906.
9. Crowson CS, Myasoedova E, Davis JM 3rd, Matteson EL, Roger VL, Therneau TM et al. Increased Prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease. J Rheumatol 2011; 38(1):29-35.
10. Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008; 196(2):756-63.
11. Steiner G, Urowitz MB. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin Arthritis Rheum 2009; 38(5):372-81.
12. Solomon DH, Love TJ, Canning C, Schneeweiss S. Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. Ann Rheum Dis 2010; 69(12):2114-7.
13. van Halm VP, Peters MJ, Voskuyl AE, Boers M, Lems WF, Visser M et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 2009; 68(9):1395-400.
14. Panoulas VF, Douglas KM, Milionis HJ, Stavropoulos-Kalinglou A, Nightingale P, Kita MD et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 2007; 46(9):1477-82.
15. Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 2011; 70(1):8-14.
16. Gonzalez A, Maradit Kremers H, Crowson CS, Ballman KV, Roger VL, Jacobsen SJ et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in nonrheumatoid arthritis patients? Ann Rheum Dis 2008; 67(1):64-9.
17. Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, Metsios GS, Nightingale P, Kita MD et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008; 47(1):72-5.
18. Alcorn N, Saunders S, Madhok R. Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf 2009; 32(12):1123-34.
19. Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev 2010; (1):CD007893.
20. Atzeni F, Turiel M, Caporali R, Cavagna L, Tomasoni L, Sitia S et al. The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. Autoimmunity Rev 2010; 9(12):835-9.
21. White WB. Defining the problem of treating the patient with hypertension and arthritis pain. Am J Med 2009; 122(5 Suppl):S3-9.
22. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69(2):325-31.
23. Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011; 305(24):2525-31.
24. Tentolouris N, Arapostathi C, Voulgari C, Grammatikou S, Andrianakos A, Sfikakis PP. The effect of diabetes mellitus on the prevalence of rheumatoid arthritis: a case-control study. Diabet Med 2008; 25(8):1010-1.
25. Han C, Robinson DW Jr., Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006; 33(11):2167-72.
26. Hoes JN, van der Goes MC, van Raalte DH, van der Zijl NJ, den Uyl D, Lems WF et al. Glucose tolerance, insulin sensitivity and β-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis 2011; 70(11):1887-94.
27. Wasko MC, Kay J, Hsia EC, Rahman MU. Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease. Arthritis Care Res (Hoboken) 2011; 63(4):512-21.
28. Antohe JL, Bili A, Sartorius JA, Lester Kirchner H, Morris SJ, Dancea S et al. Diabetes risk in rheumatoid arthritis: Reduced incidence with anti-tumor necrosis factor- α therapy. Arthritis Care Res (Hoboken) 2012; 64(2):215-21.
29. Bili A, Sartorius JA, Kirchner HL, Morris SJ, Ledwich LJ, Antohe JL et al. Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients. J Clin Rheumatol 2011; 17(3):115-20.
30. Liao KP, Gunnarsson M, Källberg H, Ding B, Plenge RM, Padyukov L et al. Specific association of type 1 diabetes mellitus with anti-cyclic citrullinated peptide-positive rheumatoid arthritis. Arthritis Rheum 2009; 60(3):653-60.
31. Choy E, Sattar N. Interpreting lipid levels in the context of highgrade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009; 68(4):460-9.
32. White D, Fayez S, Doube A. Atherogenic lipid profiles in rheumatoid arthritis. N Z Med J 2006; 119(1240):U2125.
33. Nurmohamed MT. Atherogenic lipid profiles and its management in patients with rheumatoid arthritis. Vasc Health Risk Manag 2007; 3(6):845-52.
34. Myasoedova E, Crowson CS, Kremers HM, Fitz-Gibbon PD, Therneau TM, Gabriel SE. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis 2010; 69(7):1310-4.
35. Ghosh UC, Roy A, Sen K, Kundu AK, Saha I, Biswas A. Dyslipidaemia in rheumatoid arthritis in a tertiary care centre in Eastern India - a non-randomised trial. J Indian Med Assoc 2009; 107(7):427-30.
36. Garciaa-Gómez C, Nolla JM, Valverde J, Gómez-Gerique JA, Castro MJ, Pintó X. Conventional lipid profile and lipoprotein(a) concentrations in treated patients with rheumatoid arthritis. J Rheumatol 2009; 36(7):1365-70.
37. Steiner G, Urowitz MB. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin Arthritis Rheum 2009; 38(5):372-81.
38. Georgiadis AN, Papavasiliou EC, Lourida ES, Alamanos Y, Kostara C, Tselepis AD et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment - a prospective, controlled study. Arthritis Res Ther 2006; 8(3):R82.
39. Svenson KL, Lithell H, Hallgren R, Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and disease-modifying drug treatment. Arch Intern Med 1987; 147(11):1917-20.
40. Raynauld JP. Cardiovascular mortality in rheumatoid arthritis: how harmful are corticosteroids? J Rheumatol 1997; 24(3):415-6.
41. Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990; 89(3):322-6.
42. van Halm VP, Nielen MM, Nurmohamed MT, van Schaardenburg D, Reesink HW, Voskuyl AE et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007; 66(2):184-8.
43. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database of Systematic Reviews. J Rheumatol 2011; 38(1):10-20.
44. Storage SS, Agrawal H, Furst DE. Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis. Korean J Intern Med 2010; 25(1):1-17.
45. Pollono EN, Lopez-Olivo MA, Lopez JA, Suarez-Almazor ME. A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis. Clin Rheumatol 2010; 29(9):947-55.
46. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004; 363(9426):2015-21.
47. Chatterjee Adhikari M, Guin A, Chakraborty S, Sinhamahapatra P, Ghosh A. Subclinical atherosclerosis and endothelial dysfunction in patients with early rheumatoid arthritis as evidenced by measurement of carotid intima-media thickness and flow-mediated vasodilatation: an observational study. Semin Arthritis Rheum 2012 41(5):669-75.
48. González-Juanatey C, Llorca J, González-Gay MA. Correlation between endothelial function and carotid atherosclerosis in rheumatoid arthritis patients with long-standing disease. Arthritis Res Ther 2011; 13(3):R101.
49. Pereira IA, Laurindo IM, Zimmermann AF, Werner Castro GR, Mello F, Borba EF. Single measurements of C-reactive protein and disease activity scores are not predictors of carotid atherosclerosis in rheumatoid arthritis patients. Acta Reumatol Port 2009; 34(1):58-64.
50. Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005; 52(10):3045-53.
51. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005; 52(2):402-11.
52. Nicola PJ, Maradit-Kremers H, Roger VL, Jacobsen SJ, Crowson CS, Ballman KVet al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 2005; 52(2):412-20.
53. Westlake SL, Colebatch AN, Baird J, Kiely P, Quinn M, Choy E et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2010; 49(2):295-307.
54. Westlake SL, Colebatch AN, Baird J, Curzen N, Kiely P, Quinn M et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2011; 50(3):518-31.
55. Barnabe C, Martin BJ, Ghali WA. Systematic review and metaanalysis: anti-tumor necrosis factor a therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011; 63(4):522-9.
56. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbøl EL et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med 2009; 169(2):141-9.
57. Solomon DH, Glynn RJ, Rothman KJ, Schneeweiss S, Setoguchi S, Mogun H et al. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal anti-inflammatory drugs and coxibs in specific patient groups. Arthritis Rheum 2008; 59(8):1097-104.
58. Söderlin M, Petersson I, Bergman S, Svensson B; BARFOT study group. Smoking at onset of rheumatoid arthritis (RA) and its effect on disease activity and functional status: experiences from BARFOT, a long-term observational study on early RA. Scand J Rheumatol 2011; 40(4):249-55.
59. Saevarsdottir S, Wedrén S, Seddighzadeh M, Bengtsson C, Wesley A, Lindblad S et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum 2011; 63(1):26-36.
60. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome - a new worldwide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23(5):469-80.
61. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 2001; 285(19):2846-97.
62. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. [Executive summary]. Circulation 2005; 112(17):e285-e290.
63. Santos MJ, Fonseca JE. Metabolic syndrome, inflammation and atherosclerosis - the role of adipokines in health and in systemic inflammatory rheumatic diseases. Acta Reumatol Port 2009; 34(4):590-8.
64. Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008; 196(2):756-63.
65. Sidiropoulos PI, Karvounaris SA, Boumpas DT. Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology, and clinical implications. Arthritis Res Ther 2008; 10(3):207.
66. Pereira RM, de Carvalho JF, Bonfa E. Metabolic syndrome in rheumatological diseases. Autoimmun Rev 2009; 8(5):415-9.
67. da Cunha V, Brenol C, Brenol J, Fuchs S, Arlindo E, Melo I et al. Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity. Scand J Rheumatol 2012; 41(3):186-91.
68. Karvounaris SA, Sidiropoulos PI, Papadakis JA, Spanakis EK, Bertsias GK, Kritikos HD et al. Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, crosssectional, controlled, study. Ann Rheum Dis 2007; 66(1):28-33.
69. Dessein PH, Tobias M, Veller MG. Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol 2006; 33(12):2425-32.
70. La Montagna G, Cacciapuoti F, Buono R, Manzella D, Mennillo GA, Arciello A et al. Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis. Diab Vasc Dis Res 2007; 4(2):130-5.
71. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010; 56(14):1113-32.
72. da Cunha VR, Brenol CV, Brenol JC, Xavier RM. Rheumatoid arthritis and metabolic syndrome. Rev Bras Reumatol 2011; 51(3):260-8.
73. Toms TE, Panoulas VF, John H, Douglas KM, Kitas GD. Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60 - more than just an anti-inflammatory effect? A cross sectional study. Arthritis Res Ther 2009; 11(4):R110.
74. Bacani AK, Gabriel SE, Crowson CS, Heit JA, Matteson EL. Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? Arthritis Rheum 2012; 64(1):53-61.
75. Matta F, Singala R, Yaekoub AY, Najjar R, Stein PD. Risk of venous thromboembolism with rheumatoid arthritis. Thromb Haemost 2009; 101(1):134-8.
76. Aksu K, Donmez A, Keser G. Inflammation-induced thrombosis: mechanisms, disease associations and management. Curr Pharm Des 2012; 18(11):1478-93.
77. Undas A, Gissel M, Kwasny-Krochin B, Gluszko P, Mann KG, Brummel-Ziedins KE. Thrombin generation in rheumatoid arthritis: dependence on plasma factor composition. Thromb Haemost 2010; 104(2):224-30.
78. Bisoendial RJ, Levi M, Tak PP, Stroes ES. The prothrombotic state in rheumatoid arthritis: an additive risk factor for adverse cardiovascular events. Semin Thromb Hemost 2010; 36(4):452-7.
79. Mameli A, Barcellona D, Marongiu F. Rheumatoid arthritis and thrombosis. Clin Exp Rheumatol 2009; 27(5):846-55.
80. Liang KP, Liang KV, Matteson EL, McClelland RL, Christianson TJ, Turesson C. Incidence of noncardiac vascular diseasein rheumatoid arthritis and relationship to extraarticular disease manifestations. Arthritis Rheum 2006; 54(2):642-8.
81. Davies R, Galloway JB, Watson KD, Lunt M, Symmons DP, Hyrich KL; BSRBR Control Centre Consortium, British Society for Rheumatology Biologics Register. Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70(10):1831-4.
82. Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008; 10(2):R45.
83. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005; 165(20):2337-44.
84. Hemminki K, Li X, Sundquist K, Sundquist J. Cancer risk in hospitalized rheumatoid arthritis patients. Rheumatology (Oxford) 2008; 47(5):698-701.
85. Kim YJ, Shim JS, Choi CB, Bae SC. Mortality and incidence of malignancy in Korean patients with rheumatoid arthritis. J Rheumatol 2012; 39(2):226-32.
86. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295(19):2275-85.
87. Thompson AE, Rieder SW, Pope JE. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 2011; 63(6):1479-85.
88. Askling J. The risk of malignancies in RA patients treated with biologics. Z Rheumatol 2010; 69(9):774-9.
89. Thomas E, Symmons DP, Brewster DH, Black RJ, Macfarlane GJ. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol 2003; 30(5):958-65.
90. Hemminki K, Liu X, Ji J, Sundquist J, Sundquist K. Autoimmune disease and subsequent digestive tract cancer by histology. Ann Oncol 2012; 23(4)927-33.
91. Hellgren K, Smedby KE, Feltelius N, Baecklund E, Askling J. Do rheumatoid arthritis and lymphoma share risk factors? A comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis. Arthritis Rheum 2010; 62(5):1252-8.
92. Miranda-Duarte A, Kraus-Weisman A, Granados J, Vill AR. Human leukocyte antigens class II genes are associated with cancer development in the autoimmune rheumatic diseases. Rev Invest Clin 2011; 63(3):236-43.
93. Strangfeld A, Hierse F, Rau R, Burmester GR, Krummel-Lorenz B, Demary W et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010; 12(1):R5.
94. Leombruno JP, Einarson TR, Keystone EC. The safety of antitumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009; 68(7):1136-45.
95. Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 2009; 68(7):1177-83.
96. Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?. Arthritis Rheum 2009; 60(11):3180-9.
97. Dixon WG, Watson KD, Lunt M, Mercer LK, Hyrich KL, Symmons DP et al. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken). 2010; 62(6):755-63. [Erratum in: Arthritis Care Res (Hoboken) 2010; 62(10):1514.]
98. Wong AK, Kerkoutian S, Said J, Rashidi H, Pullarkat ST. Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies. Clin Rheumatol 2012; 31(4):631-6.
99. Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven R, Heatley R et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011; 70(11):1895-904.
100. Askling J, Baecklund E, Granath F, Geborek P, Fored M, Backlin C et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009; 68(5):648-53.
101. Simon TA, Smitten AL, Franklin J, Askling J, Lacaille D, Wolfe F et al. Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis 2009; 68(12):1819-26.
102. Slimani S, Lukas C, Combe B, Morel J. Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort. Joint Bone Spine 2011; 78(5):484-7.
103. Forsblad D'Elia H, Larsen A, Waltbrand E, Kvist G, Mellström D, Saxne T et al. Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalized osteoporosis. Ann Rheum Dis 2003; 62(7):617-23.
104. van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54(10):3104-12.
105. Vis M, Haavardsholm EA, Bøyesen P, Haugeberg G, Uhlig T, Hoff M et al. High incidence of vertebral and non-vertebral fractures in the OSTRA cohort study: a 5-year follow-up study in postmenopausal women with rheumatoid arthritis. Osteoporos Int 2011; 22(9):2413-9.
106. Edwards CJ, Williams E. The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis. Osteoporos Int 2010; 21(8):1287-93.
107. Daoussis D, Andonopoulos AP, Liossis SN. Wnt pathway and IL-17: novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG axis. Semin Arthritis Rheum 2010; 39(5):369-83.
108. Yuan FL, Li X, Lu WG, Zhao YQ, Li CW, Li JP et al. Type 17 T-helper cells might be a promising therapeutic target for osteoporosis. Mol Biol Rep 2012; 39(1):771-4.
109. Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B et al. Assessment of fracture risk. Osteoporos Int 2005; 16(6):581-9.
110. Broy SB, Tanner SB; FRAX® Position Development Conference Members. Official Positions for FRAX® clinical regarding rheumatoid arthritis from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J Clin Densitom 2011; 14(3):184-9.
111. Tourinho TF, Capp E, Brenol JC, Stein A. Physical activity prevents bone loss in premenopausal women with rheumatoid arthritis: a cohort study. Rheumatol Int 2008; 28(10):1001-7.
112. de Jong Z, Munneke M, Lems WF, Zwinderman AH, Kroon HM, Pauwels EK et al. Slowing of bone loss in patients with rheumatoid arthritis by long-term high-intensity exercise: results of a randomized, controlled trial. Arthritis Rheum 2004; 50(4):1066-76.
113. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S et al.; Scientific Advisory Council of Osteoporosis Canada. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010; 182(17):1864-73.
114. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010; 62(11):1515-26.
115. Mota LMH, Cruz BA, Brenol CV, Pereira IA, Fronza LS, Bertolo MB et al. 2011 Consensus of the Brazilian Society of Rheumatology for diagnosis and early assessment of rheumatoid arthritis. Rev Bras Reumatol 2011; 51(3):199-219.
116. da Mota LM, Cruz BA, Brenol CV, Pereira IA, Rezende-Fronza LS, Bertolo MB et al. 2012 Brazilian Society of Rheumatology Consensus for the treatment of rheumatoid arthritis. Rev Bras Reumatol 2012; 52(2):152-74.